Independent Research set a €69.00 ($80.23) target price on Bayer (FRA:BAYN) in a research report released on Thursday. The firm currently has a neutral rating on the healthcare company’s stock.

Other equities analysts also recently issued reports about the stock. Goldman Sachs Group set a €116.00 ($134.88) target price on shares of Bayer and gave the stock a buy rating in a report on Wednesday, September 5th. Barclays set a €105.00 ($122.09) target price on shares of Bayer and gave the stock a buy rating in a report on Thursday, September 6th. JPMorgan Chase & Co. reiterated a buy rating on shares of Bayer in a report on Monday, October 22nd. Deutsche Bank set a €127.00 ($147.67) target price on shares of Bayer and gave the stock a buy rating in a report on Thursday, October 25th. Finally, Commerzbank set a €99.00 ($115.12) target price on shares of Bayer and gave the stock a buy rating in a report on Tuesday, November 27th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Bayer presently has an average rating of Buy and an average target price of €90.80 ($105.58).

Shares of BAYN stock traded up €1.61 ($1.87) on Thursday, hitting €63.98 ($74.40). The stock had a trading volume of 3,769,806 shares. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: What is Cost of Capital?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.